NGM · —
BHST (BHST) Stock
$2.56
+1.19%
NGM: BHST
—
Valuation
Financials & Margins
Annual Financials (USD)
Balance Sheet (USD)
Latest News
BioHarvest Sciences to Participate in the "Health, Wellness & Longevity" Virtual Conference Presented by Maxim Group LLC
TMX Newsfile · Jul 13, 2026
BioHarvest Sciences to Present at the 2026 BIO International Convention
TMX Newsfile · Jun 18, 2026
BioHarvest Sciences and Tate & Lyle expand sweetener development program
Proactive · May 19, 2026
BioHarvest (BHST) Q1 2026 Earnings Transcript
Motley Fool · May 18, 2026
Tate & Lyle Expands Collaboration with BioHarvest Sciences to Accelerate Next-Generation Sweetener Innovation
TMX Newsfile · May 18, 2026
Cash Flow (USD)
Valuation & Return Ratios
Ownership
Insiders Held14.77%
Institutions Held7.80%
Institutions Float Held9.15%
Peer Comparison
About BHST
BHST is led by CEO Ilan Sobel, publicly traded since 2021.
BHST stock trades at $2.56 with a market capitalization of $44.36M. The stock is valued at a price-to-earnings (P/E) ratio of -6.43, price-to-book of 2.68, price-to-sales of 1.90. Over the past 52 weeks the stock has ranged between $1.85 and $12.80, and currently trades 80.0% below its 52-week high.
On profitability, BHST generates a return on equity (ROE) of -44.00%, return on capital employed of -23.08%, an operating margin of -17.14%, a net profit margin of -32.54%.